|
Ventricular hypertrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction.
|
28819685 |
2017 |
|
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Specifically, DDAH1 is implicated in establishment of a vascular network by tumour cells, vasculogenic mimicry (VM), which is strongly associated with tumour progression and poor patient prognosis.
|
30611984 |
2019 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Using overexpression of DDAH1 in PCa (PC3 and LNCaP) cell lines, we found that DDAH1 promotes cell proliferation, migration and invasion by lowering ADMA levels, as well as increasing NO production.
|
29150732 |
2018 |
|
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Functional assays confirmed that forced expression of DDAH1 in the GC cells suppressed cell migration and invasion in vitro, as well as metastatic potential in vivo.
|
28580735 |
2017 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Circ-EZH2 knockdown reverses DDAH1 and CBX3-mediated cell growth and invasion in glioma through miR-1265 sponge activity.
|
31669648 |
2020 |
|
Stomach Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we found that downregulation of DDAH1 was frequently detected in GC tissues and strongly correlated with more aggressive phenotypes and poor prognosis.
|
28580735 |
2017 |
|
Steatohepatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Innovation and Conclusion: Our results provide the first direct evidence that the ADMA/DDAH1 pathway has a marked effect on hepatic lipogenesis and steatosis induced by HFD feeding.
|
27565538 |
2017 |
|
Sleeplessness
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Procyanidin B2 from lotus seedpod regulate NO/ADMA/DDAH pathway to treat insomnia in rats.
|
30861604 |
2019 |
|
Septicemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Inhibition of Dimethylarginine Dimethylaminohydrolase 1 Improves the Outcome of Sepsis in Pregnant Mice.
|
31821207 |
2019 |
|
Sepsis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Inhibition of Dimethylarginine Dimethylaminohydrolase 1 Improves the Outcome of Sepsis in Pregnant Mice.
|
31821207 |
2019 |
|
Right Ventricular Hypertrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, DDAH1 knockout significantly aggravated monocrotaline-induced lung and RV oxidative stress, lung vascular remodeling and fibrosis, pulmonary hypertension and RV hypertrophy in rats.
|
31402164 |
2019 |
|
Rheumatoid Arthritis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The results of our study give no evidence to suggest that increased ADMA levels in RA relate to DDAH genetic polymorphisms.
|
25194333 |
2014 |
|
Renal fibrosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
MicroRNA21 promotes interstitial fibrosis via targeting DDAH1: a potential role in renal fibrosis.
|
26455824 |
2016 |
|
Renal fibrosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Innovation and Conclusion: Our results provide the first direct evidence that the DDAH1 has a marked effect on kidney fibrosis and oxidative stress induced by aging or diabetes.
|
28594240 |
2017 |
|
Pulmonary Fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, DDAH1 knockout significantly aggravated monocrotaline-induced lung and RV oxidative stress, lung vascular remodeling and fibrosis, pulmonary hypertension and RV hypertrophy in rats.
|
31402164 |
2019 |
|
Prostate carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA).
|
29150732 |
2018 |
|
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Increased DDAH1 expression and subsequent increased NO production have been recently linked to cancer.
|
30611984 |
2019 |
|
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Increased DDAH1 expression and NO production have been linked to multiple pathological conditions including cancer.
|
28580735 |
2017 |
|
Portal Hypertension
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our data support translational studies, targeting DDAH-1 in cirrhosis and portal hypertension.
|
25152204 |
2015 |
|
Portal Hypertension
|
0.020 |
Biomarker
|
disease |
BEFREE |
This study supports a role for the DDAH1/ADMA axis on the effect of inflammation and oxidative stress in PH and provides insight for new therapies.
|
29263339 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our findings suggest that strategies to increase DDAH1 activity in hepatocytes may provide a novel approach to attenuate NAFLD development.Antioxid.Redox Signal.26, 598-609.
|
27565538 |
2017 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
VEGF, HIF-1α and iNOS expression did not differ in DDAH1 mutant-positive tumors compared to control tumors, but was upregulated in wild-type DDAH1 overexpressing tumors.
|
29150732 |
2018 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
However, overexpression of DDAH I had no measurable effect on tumour growth, vessel density, function or maturation.
|
29721731 |
2018 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
DDAH-1 expression was significantly induced in primary HCC tumors compared to non-tumorous background liver.
|
28741166 |
2017 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
These findings suggest that DDAH1 functions as a tumor suppressor in GC and may be exploited as a diagnostic and prognostic biomarker for GC.
|
28580735 |
2017 |